Maximuscle Ltd

Maximuscle Ltd is a UK-based company specializing in sports nutrition, offering a range of premium products designed to enhance athletic performance, recovery, and overall fitness. Founded in 1995 in the UK, Maximuscle Ltd focuses on sports nutrition products, having undergone a significant transition with its acquisition by GlaxoSmithKline in December 2010 for GBP 162 million from Darwin Private Equity. As a key player in its sector, the company has executed three notable deals, with the latest in December 2010, reflecting its strategic positioning within the market. Maximuscle specializes in high-quality sports nutrition products, including protein powders, hydration solutions, and performance supplements.

Their offerings, such as MaxWhey, Promax, and Progain, utilize scientifically-backed formulations designed to support muscle growth and recovery, catering to a diverse clientele from elite athletes to fitness novices. Marketed primarily in the UK, their products have a global distribution network. In 2011, Maximuscle reported a revenue of GBP 59,971,085. 50, with an EBITDA of GBP 1,899,373.

80, showcasing its robust financial performance in the sports nutrition market. Maximuscle plans to expand its product line with new protein formulations set to launch in late 2023, targeting both existing and new customer segments. The company aims to penetrate international markets, particularly in Europe and Asia, by 2024. The acquisition by GlaxoSmithKline provides substantial resources, allowing Maximuscle to invest in product innovation and marketing strategies that support this growth.